Longevity PapersAbout
← All papers
RESEARCH PAPER / 2025-12-09

The glycolytic enzyme PFKFB3 alleviates DNA damage and chondrocyte senescence in osteoarthritis.

Bo Liu, Chenzhong Wang, Ziyu Weng, Yi Yang, Yi Shi, Chi Zhang

Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. · pubmed

Abstract

Chondrocyte senescence is a key driver of osteoarthritis (OA) progression. This study examined the role of the glycolytic enzyme PFKFB3 in regulating chondrocyte senescence during OA. Using a destabilization of the medial meniscus (DMM) mouse model, we found that PFKFB3 expression was reduced in human and mouse OA cartilage and in hydrogen peroxide-treated chondrocytes. PFKFB3 knockdown or overexpression in primary chondrocytes was achieved through RNA interference or lentiviral delivery, followed by RNA sequencing and molecular analyses. PFKFB3 loss impaired DNA damage repair, activated NF-κB signaling, elevated pro-inflammatory cytokines, and promoted chondrocyte senescence, whereas PFKFB3 overexpression enhanced DNA repair and alleviated OA severity. Pharmacologic inhibition of NF-κB reduced inflammatory and senescent phenotypes in PFKFB3-deficient chondrocytes. These findings indicate that PFKFB3 regulates chondrocyte senescence via NF-κB signaling and DNA damage responses, suggesting PFKFB3 as a potential therapeutic target for OA.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

PFKFB3 regulates chondrocyte senescence via NF-κB signaling and DNA damage responses in osteoarthritis. The study addresses a mechanism related to cellular senescence, which is a key aspect of aging and age-related diseases, suggesting potential therapeutic avenues for mitigating OA and possibly extending healthspan.

Author of this paper? Send a correction.